These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 30293207)

  • 1. Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Armstrong N; Ramaekers BLT; Pouwels X; Lang S; Petersohn S; Riemsma R; Worthy G; Stirk L; Ross J; Kleijnen J; Joore MA
    Pharmacoeconomics; 2019 May; 37(5):655-667. PubMed ID: 30293207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
    Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Fayter D; Ramaekers BLT; Petersohn S; Riemsma R; Armstrong N; Pouwels X; Witlox W; Noake C; Worthy G; Kleijnen J; Joore MA
    Pharmacoeconomics; 2019 Oct; 37(10):1195-1207. PubMed ID: 30895564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Claxton L; O'Connor J; Woolacott N; Wright K; Hodgson R
    Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
    Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
    Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Otten T; Riemsma R; Wijnen B; Armstrong N; Stirk L; Gordon C; Ramaekers B; Kleijnen J; Joore M; Grimm S
    Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
    Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
    Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox W; Grimm S; Howick J; Armstrong N; Ahmadu C; McDermott K; Otten T; Noake C; Wolff R; Joore M
    Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
    Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox WJA; van Asselt ADI; Wolff R; Armstrong N; Worthy G; Chalker A; Buksnys T; Stirk L; Kleijnen J; Joore MA; Grimm SE
    Pharmacoeconomics; 2020 Apr; 38(4):317-324. PubMed ID: 31814080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
    Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
    Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.